Replies to post #98081 on Biotech Values

[wallstarb]

EXEL is a black hole of cash - they piss through $30m - $40m a quarter, with little to show (to date) they do seem to catch some good breaks from time to time, which allows them to not have to finance via PIPEs.

[genisi]

Scangos wants to help Tysabri's performance by a 18.7% price hike:

http://online.wsj.com/article/BT-CO-20100702-708335.html?mod=WSJ_World_MIDDLEHeadlinesEurope

Pretty big price hike. Copaxone's last price hike was 8% on May.